Narodny Onkologicky Ustav
- Address
- lock Available on a paid plan
Oncology – Solid Tumors
Narodny Onkologicky Ustav is conducting trials that explore new treatment options for prostate cancer, breast cancer, and other solid malignancies, aiming to improve survival and quality of life.
- Pre‑operative chemotherapy for high‑risk retroperitoneal sarcoma
- Combination of XL092 with immunotherapy for non‑clear cell renal cell carcinoma
- Androgen deprivation therapy plus darolutamide for metastatic prostate cancer
- Novel oral degrader ARV‑471 versus standard endocrine therapy in advanced breast cancer
The research emphasizes personalized approaches and integrates surgical and systemic strategies to advance care for patients across Bratislava and beyond.
Oncology – Hematologic Malignancies
Clinical studies at the site focus on innovative therapies for blood cancers such as follicular lymphoma and diffuse large B‑cell lymphoma, seeking to extend remission periods and reduce disease burden.
- CAR‑T cell therapy tisagenlecleucel compared with standard care for relapsed follicular lymphoma
- Epcoritamab combined with R‑CHOP versus R‑CHOP alone for newly diagnosed diffuse large B‑cell lymphoma
These trials highlight the institution’s commitment to bringing cutting‑edge immunotherapies to patients in Central Europe.
Cardiovascular – Anticoagulation Management
A dedicated trial evaluates rapid reversal agents for patients on factor Xa inhibitors, aiming to safely manage bleeding risk during urgent procedures.
- Andexanet alfa versus usual care for intra‑operative hemostasis in patients requiring urgent surgery
By addressing critical bleeding scenarios, the study supports safer surgical outcomes for individuals on modern anticoagulant therapy.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 6 therapeutic areas and 15 of 126 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 111 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 13 by active trials.
- 1Pfizer Inc.5active
lock +12 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Pfizer Inc.13trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 353 other sites in Slovakia
Therapeutic Area Benchmark — Slovakia
Select a therapeutic area to compare against other sites in Slovakia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Slovakia
Market Share
Country: Slovakia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Narodny Onkologicky Ustav
lock Showing 1 of 40 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects with Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | Exelixis Inc. | Phase III | Not Yet Recruiting | Jul 2023 | — |
IMP list
lock Showing 1 of 126 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Enzalutamide | 6 | Unknown | 2021-06-16 | 2026-03-24 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.